Skip to main content
. Author manuscript; available in PMC: 2019 Jan 1.
Published in final edited form as: Breast Cancer Res Treat. 2017 Sep 16;167(1):107–116. doi: 10.1007/s10549-017-4503-2

Figure 3. Tumor Content and DNA Methylation of Tumors in Vorinostat vs Placebo Arms.

Figure 3

Tumor content in paired samples of the same individual. Change between baseline and D15 tumor content (% tumor in biopsy section) and methylation was quantified using Wilcoxon matched pairs test. Significant reductions in both tumor content and methylation were observed at D15 within the study population (“All patients”), as well as vorinostat and placebo groups. Only samples having methylation values for all 10 genes were evaluated.